

Case Report

Secretory Carcinoma of Minor Salivary Gland in Buccal Mucosa: A Case Report and Review of the Literature

Durga Paudel ¹, **Michiko Nishimura**,¹ **Bhoj Raj Adhikari**,¹ **Daichi Hiraki**,¹ **Aya Onishi**,¹ **Tetsuro Morikawa**,¹ **Puja Neopane**,¹ **Sarita Giri**,² **Koki Yoshida**,¹ **Jun Sato**,¹ **Masayuki Ono**,³ **Yoshitaka Kamino**,³ **Hiroki Nagayasu**,⁴ and **Yoshihiro Abiko** ¹

¹*Division of Oral Medicine and Pathology, Department of Human Biology and Pathophysiology, School of Dentistry, Health Sciences University of Hokkaido, 1757 Kanazawa, Ishikari-Tobetsu, Hokkaido 061-0293, Japan*

²*Division of Periodontology and Endodontology, Department of Oral Rehabilitation, School of Dentistry, Health Sciences University of Hokkaido, 1757 Kanazawa, Ishikari-Tobetsu, Hokkaido 061-0293, Japan*

³*Sapporo Oral & Maxillofacial Surgery Clinic, Sapporo, Japan*

⁴*Division of Oral and Maxillofacial Surgery, Department of Human Biology and Pathophysiology, School of Dentistry, Health Sciences University of Hokkaido, 1757 Kanazawa, Ishikari-Tobetsu, Hokkaido 061-0293, Japan*

Correspondence should be addressed to Yoshihiro Abiko; yoshi-ab@hoku-iryu-u.ac.jp

Received 5 February 2019; Revised 13 March 2019; Accepted 18 March 2019; Published 27 March 2019

Academic Editor: Janina Kulka

Copyright © 2019 Durga Paudel et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Secretory carcinoma (SC) of the salivary gland was recently added to the fourth edition of the World Health Organization classification of head and neck tumors. Some salivary tumors, including acinic cell carcinoma, have been reclassified as SC. Most of these tumors are located on the parotid gland with very few cases reported in the minor salivary glands of the buccal mucosa. Herein, we present a case of SC of buccal mucosa, which appeared clinically as a benign lesion in a 54-year-old Japanese female patient. Histopathologically, the tumor cells presented with an eosinophilic cytoplasm with microcytic structure along with eosinophilic secretory material and hemosiderin deposit. Immunohistochemical staining revealed strongly positive staining for S100, vimentin, and mammaglobin and negative staining for DOG-1. The tumor was finally diagnosed as secretory carcinoma of the buccal mucosa. We present a review of the medical literature of SC arising from minor salivary glands. We found only 15 cases of SC of buccal mucosa out of 63 cases of SC in the minor salivary glands. They showed good prognoses and only one case of SC in the buccal mucosa exhibited local recurrence and lymph node metastases.

1. Introduction

Secretory carcinoma (SC) is a rare salivary gland tumor and has been recently included in the fourth edition of the World Health Organization classification of head and neck tumors [1]. It is also known as mammary analogue secretory carcinoma since initially described by Skalova A et al. in 2010 through a series of 16 cases [2]. Most of the cases of this carcinoma have been located in the parotid gland, and only some were reported in minor salivary glands [2–4]. Herein, we report a case of SC in the minor salivary gland of the buccal mucosa and present a review of the medical literature regarding this condition.

2. Case Presentation

A 54-year-old Japanese female visited an oral surgery clinic with a complaint of swelling in the inner region of the left cheek for the past one month. On clinical examination, a mobile swelling (size, 1 cm x 0.75 cm) with a clear boundary was observed on the left buccal mucosa. No associated pain was reported and the overlying mucosa was normal in appearance. The swelling was clinically diagnosed as benign buccal mucosa tumor. The tumor was excised under local anesthesia and was diagnosed as acinic cell carcinoma (AcCC) after histopathological examination. The margins were still positive for the tumor and further resection




FIGURE 1: Clinical presentation of the tumor. Surgical scar on left buccal mucosa (seen inside circle) (a). The residual tumor after excision (b).

was advised. The patient reported to the Health Sciences University of Hokkaido Hospital for resection of the residual tumor two months after the initial surgery. Clinically, the patient was asymptomatic. The level 1B lymph nodes on both sides were palpable, bean sized, mobile, elastic, and soft. Intraorally, a surgical scar of about 7 mm was present on left buccal mucosa. There was no pain on pressure in the region of the scar (Figure 1(a)). The patient had a history of noninvasive ductal carcinoma (ductal carcinoma in situ [DCIS]; T_{1s} N₀M₀) in the right breast, which was treated by excision and 57 Gy of radiotherapy five months ago. On investigation for oral lesion, no obvious abnormalities were detected on the computed tomography- (CT-) scan, contrast MRI, and ultrasonogram. Positron emission tomography- (PET-) CT did not suggest transition to and from any of the distant organs. The margin was resected under general anesthesia and sent for histopathological examination (Figure 1(b)). No relation to the parotid gland was found at the time of surgery.

Histopathologically, the excised margin appeared as a fragmented tissue with no encapsulation. The tumor tissue was composed of cells with dominant microcystic structure with eosinophilic cytoplasm and eosinophilic secretory material. Papillary and tubular pattern of cell arrangement were also found but were limited to small area. A few vacuolar cells and some areas with hemosiderin deposition were observed. Furthermore, normal muscle tissue and atrophied salivary gland tissues were also seen (Figure 2).

The secretory material was positive for diastase digested Periodic acid-Schiff (d-PAS), Mucicarmine, and Alcian Blue staining. No zymogen granules were found in the tumor cells. Immunohistochemistry (IHC) revealed strong positive reactions to vimentin, cytokeratin-19, and S100 protein. Mammaglobin was strongly positive, whereas discovered on gastrointestinal stromal tumors 1 (DOG-1) showed a negative reaction (Figure 3). The histological sections of breast carcinoma were examined in suspicion of metastases; however, features of ductal carcinoma in situ that appeared completely different from those of buccal mucosa tumor were noted. Based on these histomorphologic and IHC profiles, the case was diagnosed as SC of the minor salivary gland in the buccal mucosa.

3. Discussion

SC of salivary glands has been recently included in the fourth edition of the World Health Organization classification of head and neck tumors [1]. Since its description by Skalova et al. in 2010, some salivary tumors, including AcCC, have been reclassified as SC [2]. The majority of these cases were found in major salivary glands, with less frequency in minor salivary glands [2–4]. Our review showed that 63 cases of SC of minor salivary glands have been reported (Table 1). Among them, only 15 cases were found in buccal mucosa. The lip was the most affected site (21 cases) followed by palate (17 cases). Two cases were reported in tongue, labial mucosa, and retro molar gingiva each and 1 case in floor of mouth. The mean age of these patients was 48.1 years (range: 5–86 years). Only 2 cases were found in pediatric population [13, 18]. The sizes of the tumors ranged between 0.3 and 3.0 cm (mean 1.2cm). Among 42 cases which specified tumor size, more than half (24 cases) were of size ≤ 1 cm. Only 6 cases which were ≥ 2 cm were reported. Most of the tumors presented as a slow growing and painless mass. The only aggressive tumor was in hard palate which showed slow growth for 36 months but was aggressive for 2 months [23]. Two patients with tumor at hard palate complained of pain with ulceration [15, 22]. Lymph node metastases occurred in only 4 patients [2, 6, 23, 28] and local recurrence was reported in 4 patients [7, 23, 28]. These clinical features indicate that SC in the minor salivary glands may have a good prognosis with rare recurrence and lymph node metastases.

The present case was clinically diagnosed with benign buccal mucosa tumor. The small size of the tumor with a regular border, slow growth, normal overlying mucosa, and absence of pain suggested the lesion might be benign. Therefore, the resection margins were maintained close to the tumor. However, the margins were positive on histopathological examination, necessitating additional surgery for removal of residual tumor, which was subsequently diagnosed as SC. This discrepancy in clinical and pathological diagnosis might be due to the indolent clinical behavior of SC arising in the minor salivary gland of buccal mucosa. Our case needed to be ruled out for metastases from breast carcinoma since the patient had a history of breast DCIS. The PET-CT did not show any signs of metastases,




FIGURE 2: Histopathological features of SC. The excised tissue with areas of minor salivary gland (shown in inset) (a). The mass was composed of tumor cells with eosinophilic cytoplasm and had a microcystic, tubular, papillary cystic structure with eosinophilic secretory material (b, c). Few areas with hemosiderin deposition were also recognized (c). The secretory component stained positive for d-PAS (d).

and the histopathological sections of breast DCIS appeared completely different from the SC in the buccal mucosa. The possibility of metastasis of the breast carcinoma could be completely ruled out.

The differential diagnosis of SC includes AcCC, low-grade cribriform cystadenocarcinoma, low-grade mucoepidermoid carcinoma, and polymorphous low-grade adenocarcinoma [3]. Most of the cases of SC were previously diagnosed as AcCC because of their histopathological similarities. Nevertheless, some histomorphological findings are more common in SC than in AcCC. Few authors reported that the presence of papillary cystic and microcystic patterns with vacuolated cells is characteristic of SC [32, 33]. Hemosiderin deposition was also more commonly observed in SC than in AcCC [34]. In the present case, the absence of zymogen granules and presence of microcystic pattern with eosinophilic cytoplasm and eosinophilic secretory material were suggestive of SC rather than AcCC. Few areas of hemosiderin deposition along with vacuolated cells and the papillary cystic arrangement of cell also favored a diagnosis toward SC rather than AcCC.

The sections stained positive for cytokeratin-19, S100 protein, vimentin, and mammaglobin. S100 and vimentin were strongly expressed as has been reported earlier in SC. Mammaglobin is related to a family of secretory proteins; it is expressed in normal breast cells and overexpressed in

carcinomatous breast cells [35]. Strong positive reaction to mammaglobin was noted in the present case, which suggested the presence of a mammary analogue secretory component in the tumor cells. The DOG-1 protein is known to be expressed in normal salivary gland tissues, especially in the apical portions of acinic cells and few areas of the intercalated duct cells [36]. This marker can be utilized to rule out the presence of the acinic component in suspected cases of SC. A negative reaction to DOG-1 was noted in the current case thereby ruling out a diagnosis of AcCC.

The histological, immunohistochemical, and genetic appearance of SC of salivary gland is similar to that of breast secretory carcinoma. A balanced translocation $t(12:15)(p13:q25)$ resulting in ETV6-NTRK3 fusion is seen in SC [2]. Most cases have been confirmed by the demonstration of a break apart or fusion gene by fluorescence in situ hybridization or polymerase chain reaction. However, with increasing numbers of retrospective studies, it was demonstrated that the result of the histomorphologic features and IHC profile was sufficient to diagnose almost all cases of SC, while genetic analysis can be reserved for atypical cases [20, 37, 38].

4. Conclusion

This report presents a rare case of SC of buccal mucosa, which was benign in clinical presentation. In addition, a review of

TABLE 1: Reported cases of secretory carcinoma of minor salivary glands and their clinical features.

Author	Site	Age/Sex	Clinical course (Duration)	Size	LNI / DM	Treatment	Follow-up (Duration)
Abe M, 2015 [5]	Upper lip	61/F	Painless mass (1 year)	0.8	NA	NA	NA
Aizawa T, 2016 [6]	Lower lip	41/M	Slow growth, painless (3 mo)	1.5x1.3	-/-	S	LNM (26 mo)
Bishop JA, 2013 [7]	Buccal mucosa	71/M		1.0	-/-	S	
	Hard Palate	25/F		NA	-/-	S	
	Soft Palate	20/F		0.9	-/-	S	
	Soft Palate	86/F		1.0	-/-	S	
	Soft Palate	79/F	NA	0.7	-/-	S	Only 1 case of upper lip locally recurred. Mean follow-up: 42 mo (4-85mo)
	Upper lip	62/F		0.3	-/-	S	
	Upper lip	71/M		0.6	-/-	S	
	Lower lip	59/M		0.9	-/-	S	
	Lower lip	68/M		0.5	-/-	S	
	Bissinger O, 2017 [8]	Floor of mouth	34/M		0.8	-/-	S
Chiose SI, 2012 [4]			Soft palate-3 case, Buccal mucosa - 2 case, Tongue base- 1 case. Further clinical data not available				
Connor A, 2012 [9]	Oral cavity (NS)			1.8	-/-	S	
	Roof of mouth	Mean:40 y (14-77y)	NA	0.5	-/-	S	NA
	Inner cheek			NA	-/-	S	
Cooper D, 2013 [10]	Lip			1.2	-/-	S	
	Soft palate	43/M	Slow growing, painless	2.5	-/-	S	No recurrence (14 mo)
Din NU, 2016 [11]	Soft palate	26/F	Painless (7 mo)	0.7	-/-	S	No recurrence (24 mo)
	Buccal mucosa				NA		
Fehr A, 2011 [12]	Soft Palate	71/F				NA	
	Oral mucosa	43/M					
Griffith C, 2011 [13]	Upper lip	15/M	NA	NA	-/-	NA	NA
Guilmette J, 2017 [14]	Buccal mucosa	64/F	NA	0.6	-/-	NA	NA
Helkamaa T, 2015 [15]	Hard palate	35/M	Ulcerated, tender (6 mo)	2.0x1.5	-/-	S	No recurrence (18 mo)
Hindocho N, 2017 [16]	Upper lip	27/F	Slow growing (1y)	1.5	-/-	S	No recurrence
	Labial mucosa	51/M	Asymptomatic, firm (3y)		-/-	S	No recurrence
Kai K, 2017 [17]	Buccal mucosa	58/M	NA	3.0	NA	S	No recurrence (1 y)
Keishling M, 2014 [18]	Buccal mucosa	5/F	(4mo)	1.5x1.5x1.3	-/-	S	NA
Khurram SA, 2017 [19]			Buccal mucosa, Lower lip and Soft palate- 1 case each. Further clinical data not available.				
Kratochvil F, 2012 [20]	Upper lip	48/M	Slow growth, painless	1.0	-/-	S	No recurrence (8 mo)
	Labial mucosa	52/M	Painless	0.7x0.3	-/-	S	No recurrence (4 mo)
Laco J, 2013 [21]	Upper lip	34/F	Slow growing, painless (2y)	1.5	-/-	S	No recurrence (15 mo)
Luo W, 2014 [22]	Hard palate	41/F	Ulcerated crater	2.0	+/-	S+R	No recurrence (10 mo)
Majewska H, 2015 [23]	Hard palate	54/M	Slow growing, non tender (36 mo), aggressive (2 mo)	2.0x1.0	-/-	S+R	Local recurrence (48 mo), LNM

TABLE 1: Continued.

Author	Site	Age/Sex	Clinical course (Duration)	Size	LNI / DM	Treatment	Follow-up (Duration)
Mariano FV, 2016 [24] and Proietti F, 2015 [25]	each reported 1 case (no site specified). Further clinical data not available.						
Roy S, 2018 [26]	Upper lip	54/M	Slow growing, painless	1.5	-/-	S	NA
	Tongue	22/F	NA	1.5x1.5x1	NA	S	NA
Serrano ML, 2015 [27]	Buccal mucosa	41/F	Slow growing	0.5	NA	NA	NA
	Buccal mucosa	50/M	Slow growing	0.5	NA	NA	NA
Skalova A, 2010 [2]	Buccal mucosa	51/F	Slow growing, painless (1y)	1.0	-/-	S	No recurrence (4 y)
	Soft palate	48/M	Slow growing	1.0x1.5	-/-	S	No recurrence (9y)
	Upper lip	32/M	Painless but grew in size	1.0	-/-	S+R	LNM (86 mo)
	Buccal mucosa	31/F		1.0	-/-	S	No recurrence (11 mo)
	Buccal mucosa	24/F		1.0	+/-	S	LNM, Local recurrence (2y)
	Upper lip	48/M		1.0	-/-	S	Local recurrence (2 mo)
Skalova A, 2016 [28]	Lip	50/M	NA	1.5	NA	NA	NA
	Retromolar gingiva	69/F		0.6	-/-	S	No recurrence (2y)
	Retromolar gingiva	73/M		1.5x2.0x2.5	+/-	NA	NA
	Lip	62/F		1.0	-/-	S	No recurrence (3 y)
	Upper lip	44/F	NA	NA	NA	S	NA
Steven TM, 2015 [29]	Lower lip	66/M	NA	NA	NA	S	NA
	Hard palate	54/M	NA	NA	NA	S+R	No recurrence (2 y)
Urano M, 2015 [30]	Lip	40/M	(3 mo)	1.2x1.1	-/-	NA	No recurrence
Zardawi IM, 2014 [31]	Upper lip	66/M	(6 mo)	1.2x1.0x.08	-/-	S	No recurrence

LNI / DM: Lymph node involvement / Distant metastases before treatment, S: Surgery, R: Adjuvant radiotherapy, LNM: Lymph node metastases on follow-up, mo: Month, y: Year, NA: Data not available, +/-: Present/Absent




FIGURE 3: Immunohistochemical staining of the tissues. The cells were strongly positive for vimentin (a), S-100 (b), and mammaglobin (c), but negative for DOG-1 (d).

the medical literature regarding the clinical behavior of SC of minor salivary gland was performed.

Conflicts of Interest

The authors declare that there are no conflicts of interest regarding the publication of this article.

References

- [1] A. Skalova, D. Bell, J. A. Bishop, H. Inagaki, R. Seethala, and P. Vielh, "Secretory carcinoma: tumors of salivary glands," in *WHO Classification of Head and Neck Tumors*, A. K. El-Naggar, J. K. C. Chan, J. R. Grandis, T. Takata, and P. J. Slootweg, Eds., pp. 177-178, International Agency for Research on Cancer, Lyon, 4th edition, 2017.
- [2] A. Skálová, T. Vanecek, R. Sima et al., "Mammary analogue secretory carcinoma of salivary glands, containing the *etv6-ntrk3* fusion gene: a hitherto undescribed salivary gland tumor entity," *The American Journal of Surgical Pathology*, vol. 34, no. 5, pp. 599-608, 2010.
- [3] R. Sethi, E. Kozin, A. Remenschneider et al., "Mammary analogue secretory carcinoma: update on a new diagnosis of salivary gland malignancy," *The Laryngoscope*, vol. 124, no. 1, pp. 188-195, 2014.
- [4] S. I. Chiosea, C. C. Griffith, A. Assaad, and R. R. Seethala, "Clinicopathological characterization of mammary analogue secretory carcinoma of salivary glands," *Histopathology*, vol. 61, no. 3, pp. 387-394, 2012.
- [5] M. Abe, R. Inaki, Y. Kanno, K. Hoshi, and T. Takato, "Molecular analysis of a mammary analog secretory carcinoma in the upper lip. Novel search for genetic and epigenetic abnormalities in MASC," *International Journal of Surgery Case Reports*, vol. 9, pp. 8-11, 2015.
- [6] T. Aizawa, T. Okui, K. Kitagawa, Y. Kobayashi, K. Satoh, and H. Mizutani, "A case of mammary analog secretory carcinoma of the lower lip," *Journal of Oral and Maxillofacial Surgery, Medicine, and Pathology*, vol. 28, pp. 277-282, 2016.
- [7] J. A. Bishop, R. Yonescu, D. Batista, D. W. Eisele, and W. H. Westra, "Most non-parotid "acinic cell carcinomas" represent mammary analogue secretory carcinomas," *The American Journal of Surgical Pathology*, vol. 37, no. 7, pp. 1053-1057, 2013.
- [8] O. Bissinger, C. Götz, A. Kolk et al., "Mammary analogue secretory carcinoma of salivary glands: diagnostic pitfall with distinct immunohistochemical profile and molecular features," *Rare Tumors*, vol. 9, article 7162, pp. 89-92, 2017.
- [9] A. Connor, B. Perez-Ordoñez, M. Shago, A. Skálová, and I. Weinreb, "Mammary analog secretory carcinoma of salivary gland origin with the *ETV6* gene rearrangement by FISH: expanded morphologic and immunohistochemical spectrum of a recently described entity," *The American Journal of Surgical Pathology*, vol. 36, no. 1, pp. 27-34, 2012.
- [10] D. Cooper, B. Burkey, D. Chute, and J. Scharpf, "Mammary analogue secretory carcinoma of the soft palate: a report of two cases," *International Journal of Otolaryngology and Head & Neck Surgery*, vol. 2, pp. 174-178, 2013.

- [11] N. U. Din, S. Fatima, and N. Kayani, "Mammary analogue secretory carcinoma of salivary glands: a clinicopathologic study of 11 cases," *Annals of Diagnostic Pathology*, vol. 22, pp. 49–53, 2016.
- [12] A. Fehr, T. Löning, and G. Stenman, "Mammary analogue secretory carcinoma of the salivary glands with ETV6-NTRK3 gene fusion," *The American Journal of Surgical Pathology*, vol. 35, no. 10, pp. 1600–1602, 2011.
- [13] C. Griffith, R. Seethala, and S. I. Chiosea, "Mammary analogue secretory carcinoma: a new twist to the diagnostic dilemma of zymogen granule poor acinic cell carcinoma," *Virchows Archiv*, vol. 459, no. 1, pp. 117–118, 2011.
- [14] J. Guilmette, G. P. Nielsen, W. C. Faquin et al., "Ultrastructural characterization of mammary analogue secretory carcinoma of the salivary glands: a distinct entity from acinic cell carcinoma?" *Head & Neck Pathology*, vol. 11, no. 4, pp. 419–426, 2017.
- [15] T. Helkamaa, S. Rossi, K. Mesimäki et al., "Mammary analog secretory carcinoma of minor palatal salivary glands: a case report and review of the literature," *Journal of Oral and Maxillofacial Surgery, Medicine, and Pathology*, vol. 27, no. 5, pp. 698–702, 2015.
- [16] N. Hindocha, M. H. Wilson, M. Pring, C. W. Hughes, and S. J. Thomas, "Mammary analogue secretory carcinoma of the salivary glands: a diagnostic dilemma," *British Journal of Oral and Maxillofacial Surgery*, vol. 55, no. 3, pp. 290–292, 2017.
- [17] K. Kai, A. Minesaki, K. Suzuki et al., "Difficulty in the cytodiagnosis of mammary analogue secretory carcinoma: survey of 109 cytologists with a case originating from a minor salivary gland," *Acta Cytologica*, vol. 61, no. 6, pp. 469–476, 2017.
- [18] M. Keisling, M. Bianchi, and J. M. Pascasio, "Mammary analog secretory carcinoma of salivary gland in a 5 year old: case report," *International Journal of Pediatric Otorhinolaryngology Extra*, vol. 9, no. 4, pp. 163–165, 2014.
- [19] S. A. Khurram, J. Sultan-Khan, N. Atkey, and P. M. Speight, "Cytogenetic and immunohistochemical characterization of mammary analogue secretory carcinoma of salivary glands," *Oral Surgery, Oral Medicine, Oral Pathology, Oral Radiology, and Endodontology*, vol. 122, no. 6, pp. 731–742, 2016.
- [20] F. J. Kratochvil, J. C. Stewart, and S. R. Moore, "Mammary analog secretory carcinoma of salivary glands: a report of 2 cases in the lips," *Oral Surgery, Oral Medicine, Oral Pathology, Oral Radiology, and Endodontology*, vol. 114, no. 5, pp. 630–635, 2012.
- [21] J. Laco, M. Švajdler, J. Andrejs et al., "Mammary analog secretory carcinoma of salivary glands: a report of 2 cases with expression of basal/myoepithelial markers (calponin, CD10 and p63 protein)," *Pathology - Research and Practice*, vol. 209, no. 3, pp. 167–172, 2013.
- [22] W. Luo, S. W. Lindley, P. H. Lindley, G. A. Kreml, R. R. Seethala, and K.-M. Fung, "Mammary analog secretory carcinoma of salivary gland with high-grade histology arising in hard palate, report of a case and review of literature," *International Journal of Clinical and Experimental Pathology*, vol. 7, no. 12, pp. 9008–9022, 2014.
- [23] H. Majewska, A. Skálová, D. Stodulski et al., "Mammary analogue secretory carcinoma of salivary glands: a new entity associated with ETV6 gene rearrangement," *Virchows Archiv*, vol. 466, no. 3, pp. 245–254, 2015.
- [24] F. V. Mariano, C. A. Gómez, J. de Souza do Nascimento et al., "Lysozyme expression can be useful to distinguish mammary analog secretory carcinoma from acinic cell carcinoma of salivary glands," *Head & Neck Pathology*, vol. 10, no. 4, pp. 429–436, 2016.
- [25] F. Progetti, M. Lacroix-Triki, E. Serrano, S. Vergez, B. H. Barres, and J. Meilleroux, "A comparative immunohistochemistry study of diagnostic tools in salivary gland tumors: usefulness of mammaglobin, gross cystic disease fluid protein 15, and p63 cytoplasmic staining for the diagnosis of mammary analog secretory carcinoma," *Journal of Oral Pathology & Medicine*, vol. 44, pp. 244–251, 2015.
- [26] S. Roy, K. Saluja, H. Zhu, and B. Zhao, "Mammary analogue secretory carcinoma of minor salivary glands: a rare case series and review of the literature," *Annals of Clinical & Laboratory Science*, vol. 48, no. 1, pp. 94–99, 2018.
- [27] M. L. Serrano-Arévalo, A. Mosqueda-Taylor, H. Domínguez-Malagón, and M. Michal, "Mammary analogue secretory carcinoma (MASC) of salivary gland in four mexican patients," *Medicina Oral Patología Oral y Cirugía Bucal*, vol. 20, no. 1, pp. e23–e29, 2015.
- [28] A. Skalova, T. Vanecek, R. H. W. Simpson, J. Laco, H. Majewska, M. Baneckova et al., "Mammary analogue secretory carcinoma of salivary glands. Molecular analysis of 25 ETV6 gene rearranged tumors with lack of detection of classical ETV6-NTRK3 fusion transcript by standard RT-PCR: report of 4 cases harboring ETV6-X gene fusion," *The American Journal of Surgical Pathology*, vol. 40, no. 1, pp. 3–13, 2016.
- [29] T. M. Stevens, A. O. Kovalovsky, C. Velosa et al., "Mammary analog secretory carcinoma, low-grade salivary duct carcinoma and mimickers: a comparative study," *Modern Pathology*, vol. 28, no. 8, pp. 1084–1100, 2015.
- [30] M. Urano, T. Nagao, S. Miyabe, K. Ishibashi, K. Higuchi, and M. Kuroda, "Characterization of mammary analogue secretory carcinoma of the salivary gland: discrimination from its mimics by the presence of the ETV6-NTRK3 translocation and novel surrogate markers," *Human Pathology*, vol. 46, no. 1, pp. 94–103, 2015.
- [31] I. M. Zardawi and P. Hook, "Mammary analogue secretory carcinoma of minor salivary glands," *Pathology*, vol. 46, no. 7, pp. 667–669, 2014.
- [32] M.-S. Hsieh, Y.-H. Chou, S.-J. Yeh, and Y.-L. Chang, "Papillary-cystic pattern is characteristic in mammary analogue secretory carcinomas but is rarely observed in acinic cell carcinomas of the salivary gland," *Virchows Archiv*, vol. 467, no. 2, pp. 145–153, 2015.
- [33] M. J. Jung, J. S. Song, S. Y. Kim et al., "Finding and characterizing mammary analogue secretory carcinoma of the salivary gland," *The Korean Journal of Pathology*, vol. 47, no. 1, pp. 36–43, 2013.
- [34] M. S. Hsieh, Y. H. Lee, and Y. L. Chang, "SOX10-positive salivary gland tumors: a growing list, including mammary analogue secretory carcinoma of the salivary gland, sialoblastoma, low-grade salivary duct carcinoma, basal cell adenoma/adenocarcinoma, and a subgroup of mucoepidermoid carcinoma," *Human Pathology*, vol. 56, pp. 134–142, 2016.
- [35] M. A. Watson and T. P. Fleming, "Mammaglobin, a mammary-specific member of the uteroglobin gene family, is overexpressed in human breast cancer," *Cancer Research*, vol. 56, no. 4, pp. 860–865, 1996.
- [36] J. Chênevert, U. Duvvuri, S. Chiosea et al., "DOG1: a novel marker of salivary acinar and intercalated duct differentiation," *Modern Pathology*, vol. 25, no. 7, pp. 919–929, 2012.
- [37] J. A. Bishop, R. Yonescu, D. Batista, S. Begum, D. W. Eisele, and W. H. Westra, "Utility of mammaglobin immunohistochemistry as a proxy marker for the ETV6-NTRK3 translocation in the diagnosis of salivary mammary analogue secretory carcinoma," *Human Pathology*, vol. 44, no. 10, pp. 1982–1988, 2013.

- [38] N. Said-Al-Naief, R. Carlos, G. H. Vance, C. Miller, and P. C. Edwards, "Combined DOG1 and mammaglobin immunohistochemistry is comparable to ETV6-breakapart analysis for differentiating between papillary cystic variants of acinic cell carcinoma and mammary analogue secretory carcinoma," *International Journal of Surgical Pathology*, vol. 25, no. 2, pp. 127–140, 2017.